SCHEMBL6301538

SCHEMBL6301538

COC(=O)c1ccc2c(=O)n(Cc3ccc(Cl)cc3Cl)c(=O)[nH]c2c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.62
KDM4E B2RXH2 7/20 0.62
ALDH1A1 P00352 7/20 0.62
HPGD P15428 3/20 0.62
KMT2A Q03164 3/20 0.62
GLA P06280 3/20 0.62
PKM P14618 2/20 0.62
HTT P42858 2/20 0.62
HSD17B10 Q99714 2/20 0.62
MAPT P10636 5/20 0.57
MEN1 O00255 2/20 0.54
TP53 P04637 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 1/20 0.53
THRB P10828 1/20 0.53
TDP1 Q9NUW8 1/20 0.51
HTR3A P46098 2/20 0.50
CACNA1G O43497 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249457 0.88 SMN1; SMN2 (0.67) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL4252121 0.87 MAPT (0.68) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL2118623 0.82 ALDH1A1 (0.69) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL27203155 0.80 ALDH1A1 (0.61) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL4251219 0.80 ALDH1A1 (0.63) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL4248735 0.80 HTR3A (0.67) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL4253579 0.80 GAA (0.65) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL4256455 0.80 GAA (0.72) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL30414309 0.80 KMT2A (0.77) GAAKDM4EALDH1A1HPGDKMT2A
SCHEMBL6306378 0.80 KMT2A (0.77) GAAKDM4EALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 GAA 171/4885KDM4E 1305/4885ALDH1A1 570/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM GAA 146/4885KDM4E 935/4885ALDH1A1 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.